The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 02, 2025

Filed:

Mar. 29, 2018
Applicants:

The Children's Medical Center Corporation, Boston, MA (US);

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Derrick J. Rossi, Newton, MA (US);

Agnieszka D. Czechowicz, Irvine, CA (US);

Philip M. Murphy, Rockville, MD (US);

Zhanzhuo Li, North Potomac, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6849 (2017.08); A61K 35/28 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6825 (2017.08); A61P 37/06 (2018.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01);
Abstract

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34cells, and peripheral blood CD34and CD90cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.


Find Patent Forward Citations

Loading…